Recursion Pharmaceuticals (RXRX) Set to Announce Earnings on Wednesday

Recursion Pharmaceuticals (NASDAQ:RXRX) is scheduled to release its earnings data after the market closes on Wednesday, November 6th. Analysts expect Recursion Pharmaceuticals to post earnings of ($0.33) per share for the quarter.

Recursion Pharmaceuticals (NASDAQ:RXRX) last posted its quarterly earnings results on Thursday, August 8th. The company reported ($0.40) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.35) by ($0.05). Recursion Pharmaceuticals had a negative net margin of 755.37% and a negative return on equity of 79.47%. The business had revenue of $14.42 million during the quarter, compared to analyst estimates of $11.96 million. During the same period in the previous year, the business posted ($0.38) EPS. The business’s revenue for the quarter was up 30.9% compared to the same quarter last year. On average, analysts expect Recursion Pharmaceuticals to post $-2 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Recursion Pharmaceuticals Stock Performance

RXRX traded down $0.05 during trading on Tuesday, hitting $6.59. 1,696,199 shares of the company’s stock were exchanged, compared to its average volume of 5,647,177. Recursion Pharmaceuticals has a fifty-two week low of $5.03 and a fifty-two week high of $15.74. The business’s 50 day moving average is $6.61 and its two-hundred day moving average is $7.64. The company has a debt-to-equity ratio of 0.04, a quick ratio of 6.07 and a current ratio of 6.07.

Insiders Place Their Bets

In other news, COO Tina Marriott sold 6,000 shares of the company’s stock in a transaction that occurred on Thursday, August 29th. The stock was sold at an average price of $7.56, for a total value of $45,360.00. Following the completion of the transaction, the chief operating officer now directly owns 521,138 shares of the company’s stock, valued at $3,939,803.28. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. In other Recursion Pharmaceuticals news, CEO Christopher Gibson sold 30,000 shares of Recursion Pharmaceuticals stock in a transaction dated Wednesday, August 7th. The shares were sold at an average price of $7.10, for a total value of $213,000.00. Following the sale, the chief executive officer now owns 758,738 shares of the company’s stock, valued at approximately $5,387,039.80. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, COO Tina Marriott sold 6,000 shares of the stock in a transaction that occurred on Thursday, August 29th. The shares were sold at an average price of $7.56, for a total transaction of $45,360.00. Following the transaction, the chief operating officer now directly owns 521,138 shares of the company’s stock, valued at $3,939,803.28. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 201,682 shares of company stock valued at $1,320,868 in the last 90 days. 15.75% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

A number of equities research analysts recently weighed in on RXRX shares. Jefferies Financial Group lowered their target price on shares of Recursion Pharmaceuticals from $8.00 to $6.00 and set a “hold” rating on the stock in a report on Tuesday, September 3rd. Leerink Partners lowered their price objective on Recursion Pharmaceuticals from $9.00 to $8.00 and set a “market perform” rating for the company in a research note on Tuesday, September 3rd. KeyCorp dropped their target price on Recursion Pharmaceuticals from $16.00 to $12.00 and set an “overweight” rating on the stock in a report on Thursday, July 11th. Finally, Needham & Company LLC decreased their price target on Recursion Pharmaceuticals from $16.00 to $11.00 and set a “buy” rating for the company in a report on Wednesday, September 4th. Four analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average target price of $9.40.

Recursion Pharmaceuticals Company Profile

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.